Molecular Oncology
Volume 4, Issue 5 , Pages 431-442 , October 2010

Pancreatic cancer stem cells – update and future perspectives

Received 1 March 2010 ,Revised 1 June 2010 ,Accepted 1 June 2010.

References 

  1. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer. 1996;78:654–663
  2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison S, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003;100:3983–3988
  3. Bao S, Wu Q, Mclendon R, Hao Y, Shi Q, Hjelmeland A, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760
  4. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, et al Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007;25:2524–2533
  5. Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science. 2007;316:600–604
  6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997;3:730–737
  7. Bruce WR, Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature. 1963;199:79–80
  8. Burkert J, Otto W, Wright N. Side populations of gastrointestinal cancers are not enriched in stem cells. J. Pathol. 2008;214:564–573
  9. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997;15:2403–2413
  10. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells – perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006;66:9339–9344
  11. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, et al Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One. 2010;5:e10277
  12. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464:999–1005
  13. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67:2187–2196
  14. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996;183:1797–1806
  15. Hermann P, Huber S, Herrler T, Aicher A, Ellwart J, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313–323
  16. Hermann PC, Huber SL, Heeschen C. Metastatic cancer stem cells: a new target for anti-cancer therapy?. Cell Cycle. 2008;7:188–193
  17. Hermann PC, Mueller MT, Heeschen C. Pancreatic cancer stem cells – insights and perspectives. Expert Opin. Biol. Ther. 2009;9:1271–1278
  18. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437–450
  19. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2004;101:14228–14233
  20. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer. 2009;125:2323–2331
  21. Immervoll H, Hoem D, Sakariassen P, Steffensen O, Molven A. Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 2008;8:48
  22. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC–mTOR pathway in human disease. Nat. Genet. 2005;37:19–24
  23. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J. Clin. 2004;54:8–29
  24. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4:e6816
  25. Jimeno A, Feldmann G, Suarez-Gauthier A, Rasheed Z, Solomon A, Zou GM, et al A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol. Cancer Ther. 2009;8:310–314
  26. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, et al The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010;70:719–729
  27. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–1037
  28. Ma S, Chan K, Hu L, Lee T, Wo J, Ng I, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542–2556
  29. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br. J. Cancer. 2008;98:1389–1397
  30. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007;25:1960–1966
  31. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature. 2006;441:1068–1074
  32. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, et al Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009;137:1102–1113
  33. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan JW, et al Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–56
  34. Nakata B, Fukunaga S, Noda E, Amano R, Yamada N, Hirakawa K. Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer. Oncology. 2008;74:69–75
  35. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–28
  36. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay. J. Natl. Cancer Inst. 1971;46:411–422
  37. Park SW, Davison JM, Rhee J, Hruban RH, Maitra A, Leach SD. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. Gastroenterology. 2008;134:2080–2090
  38. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010;140:62–73
  39. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, et al Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J. Clin. Oncol. 2009;27:5660–5669
  40. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593–598
  41. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, et al Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl. Cancer Inst. 2010;102:340–351
  42. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111
  43. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–115
  44. Rosenberg L. Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine. Int. J. Pancreatol. 1997;22:81–93
  45. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA, et al A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 1996;7:347–353
  46. Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y. CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas. Pancreas. 2009;38:e207–214
  47. Shmelkov S, Butler J, Hooper A, Hormigo A, Kushner J, Milde T, et al CD133 expression is not restricted to stem cells, and both CD133+and CD133− metastatic colon cancer cells initiate tumors. J. Clin. Invest. 2008;14:
  48. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401
  49. Tian H, Callahan CA, DuPree KJ, Darbonne WC, Ahn CP, Scales SJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2009;106:4254–4259
  50. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer. 2008;8:755–768
  51. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 1992;326:455–465
  52. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009;11:1487–1495
  53. Wicha MS. Cancer stem cells: an old idea – a paradigm shift. Cancer Res. 2006;66:1883–1890(discussion 1895–1886)
  54. Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, et al Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135:1118–1129
  55. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, et al A paracrine requirement for hedgehog signalling in cancer. Nature. 2008;455:406–410
  56. Yilmaz Ö, Valdez R, Theisen B, Guo W, Ferguson D, Wu H, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006;441:475–482
  57. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U.S.A. 2007;104:16158–16163

PII: S1574-7891(10)00048-7

doi: 10.1016/j.molonc.2010.06.002

Molecular Oncology
Volume 4, Issue 5 , Pages 431-442 , October 2010

Article Tools

* Image Usage & Resolution